Thera-SAbDab

TESIDOLUMAB

>   Structural Summary
TherapeuticTesidolumab
TargetC5
Heavy ChainEVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS
Light ChainSYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '22)Phase-II
Estimated Status (Aug '22)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display;XmAb Engineering Technology
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedMorphoSys, Novartis
Conditions Approvedna
Conditions ActiveParoxysmal nocturnal haemoglobinuria
Conditions DiscontinuedChoroiditis, Dry age-related macular degeneration, Panuveitis, Thrombotic microangiopathy, Wet age-related macular degeneration
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy